Aquestive CCO sells 8,750 shares in option trade
AQST’s Chief Commercial Officer exercised options and sold 8,750 shares in a pre-arranged Rule 10b5-1 transaction.
Rhea-AI Filing Summary
Aquestive Therapeutics, Inc. (AQST) reported that Chief Commercial Officer Sherry Korczynski exercised stock options and sold shares on September 9, 2026. She exercised 8,750 non-qualified stock options at an exercise price of $2.65 per share, converting them into 8,750 shares of common stock, and then sold 8,750 common shares at $5.22 per share. Following the option exercise, she held 26,250 stock options directly, with the exercised option series expiring on March 7, 2035. The sales were made pursuant to a previously adopted Rule 10b5-1 Trading Plan, indicating they were pre-arranged.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 8,750 shares ($22K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Korczynski Sherry
Role
Chief Commercial Officer
Sold
8,750 shs ($46K)
Approx. gross sale proceeds
$46K
Approx. exercise cost
$23K
Approx. pre-tax spread
$22K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (right to buy) F2 | 8,750 | $0.00 | $0.00 |
| Exercise | Common Stock | 8,750 | $2.65 | $23K |
| Sale | Common Stock F1 | 8,750 | $5.22 | $46K |
Holdings After Transaction:
Non-Qualified Stock Option (right to buy) — 26,250 contracts (Direct);
Common Stock — 235,689 shares (Direct)
Footnotes (2)
- F1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4.
- F2. The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.
Key Figures
Options exercised: 8,750 options
Exercise price: $2.65 per share
Shares sold: 8,750 shares
+4 more
7 metrics
Options exercised
8,750 options
Non-qualified stock options exercised on September 9, 2026
Exercise price
$2.65 per share
Exercise price of non-qualified stock options converted into common stock
Shares sold
8,750 shares
Common stock sold on September 9, 2026 after option exercise
Sale price
$5.22 per share
Per-share price for the 8,750 common shares sold
Options held after transaction
26,250 options
Directly held non-qualified stock options following the reported exercise
Option expiration date
March 7, 2035
Expiration date of the exercised non-qualified stock option series
Net buy/sell shares
8,750 net shares sold
Net share disposition across reported buy/sell transactions
Key Terms
Non-Qualified Stock Option, Rule 10b5-1 Trading Plan, derivative security
3 terms
Non-Qualified Stock Option financial
"Non-Qualified Stock Option (right to buy)"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
Rule 10b5-1 Trading Plan regulatory
"sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What transactions did AQST’s Chief Commercial Officer report on this Form 4?
She exercised 8,750 stock options at $2.65 per share into common stock and then sold 8,750 shares of Aquestive Therapeutics, Inc. common stock at $5.22 per share on September 9, 2026, as a linked exercise-and-sell sequence.
How many AQST options does Sherry Korczynski hold after these transactions?
After the reported option exercise, she directly held 26,250 non-qualified stock options in Aquestive Therapeutics, Inc. The exercised option series has an expiration date of March 7, 2035, and the remaining options continue to be outstanding.
What prices were involved in the AQST Form 4 transactions?
The stock options were exercised at $2.65 per share, and the resulting common shares of Aquestive Therapeutics, Inc. were sold at $5.22 per share on September 9, 2026. Both prices are reported on a per-share basis in the Form 4.
What type of security did the AQST insider exercise?
She exercised non-qualified stock options (right to buy) for 8,750 underlying shares of Aquestive Therapeutics, Inc. common stock. These options carry an exercise price of $2.65 per share and an expiration date of March 7, 2035 as reported.
AI-generated analysis. How Rhea-AI works. Not financial advice.
